Dialysis Outcomes Across Countries and Regions: A Global Perspective From the International Society of Nephrology Global Kidney Health Atlas Study.

chronic kidney disease death hemodialysis hospitalization kidney failure outcomes

Journal

Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 02 03 2024
revised: 02 03 2024
accepted: 13 05 2024
medline: 19 8 2024
pubmed: 19 8 2024
entrez: 19 8 2024
Statut: epublish

Résumé

Kidney failure treated with hemodialysis (HD), or peritoneal dialysis (PD) is a major global health problem that is associated with increased risks of death and hospitalization. This study aimed to compare the incidence and causes of death and hospitalization during the first year of HD or PD among countries. The third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) was conducted between June and September 2022. For this analysis, data were obtained from the cross-sectional survey of key stakeholders from ISN-affiliated countries. A total of 167 countries participated in the survey (response rate 87.4%). In 48% and 58% of countries, 1% to 10% of people treated with HD and PD died within the first year, respectively, with cardiovascular disease being the main cause. Access-related infections or treatment withdrawal owing to cost were important causes of death in low-income countries (LICs). In most countries, <30% and <20% of patients with HD and PD, respectively, required hospitalization during the first year. A greater proportion of patients with HD and PD in LICs were hospitalized in the first year than those in high-income countries (HICs). Access-related infection and cardiovascular disease were the commonest causes of hospitalization among patients with HD, whereas PD-related infection was the commonest cause in patients with PD. There is significant heterogeneity in the incidence and causes of death and hospitalization in patients with kidney failure treated with dialysis. These findings highlight opportunities to improve care, especially in LICs where infectious and social factors are strong contributors to adverse outcomes.

Identifiants

pubmed: 39156158
doi: 10.1016/j.ekir.2024.05.014
pii: S2468-0249(24)01737-6
pmc: PMC11328589
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2410-2419

Informations de copyright

© 2024 International Society of Nephrology. Published by Elsevier Inc.

Auteurs

Emily See (E)

Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Nephrology, Royal Children's Hospital, Parkville, Victoria, Australia.
Department of Critical Care, University of Melbourne, Melbourne, Australia.

Isabelle Ethier (I)

Division of Nephrology, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Health Innovation and Evaluation Hub, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Yeoungjee Cho (Y)

Australasian Kidney Trials Network at the University of Queensland, Brisbane, Queensland, Australia.
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Htay Htay (H)

Department of Renal Medicine, Singapore General Hospital, Singapore.
Duke-NUS Medical School, Singapore.

Silvia Arruebo (S)

The International Society of Nephrology, Brussels, Belgium.

Fergus J Caskey (FJ)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Sandrine Damster (S)

The International Society of Nephrology, Brussels, Belgium.

Jo-Ann Donner (JA)

The International Society of Nephrology, Brussels, Belgium.

Vivekanand Jha (V)

George Institute for Global Health, University of New South Wales, New Delhi, India.
School of Public Health, Imperial College, London, UK.
Manipal Academy of Higher Education, Manipal, India.

Adeera Levin (A)

Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Masaomi Nangaku (M)

Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Syed Saad (S)

Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Marcello Tonelli (M)

Department of Medicine, University of Calgary, Calgary, Alberta; Canada.
Pan-American Health Organization/World Health Organization's Collaborating Centre in Prevention and Control of Chronic Kidney Disease, University of Calgary, Calgary, Alberta, Canada.

Feng Ye (F)

Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Ikechi G Okpechi (IG)

Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Division of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa.
Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa.

Aminu K Bello (AK)

Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

David W Johnson (DW)

Australasian Kidney Trials Network at the University of Queensland, Brisbane, Queensland, Australia.
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Centre for Kidney Disease Research, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Translational Research Institute, Brisbane, Queensland, Australia.

Classifications MeSH